Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D ‘Risk factors’ in the Group’s Annual Report on Form 20-F for FY 2019 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our third quarter 2020 earnings release and Annual Report on Form 20-F for FY 2019.

All expectations and targets regarding future performance and the dividend should be read together with “Assumptions related to 2020 guidance and 2016-2020 outlook” on page 63 of our third quarter 2020 earnings release.
Building 2 world leading companies

- Strengthening pipeline
- Drive operating performance
- Successful integration
- Prepare for 2 new companies

New GSK: a leading biopharma company with R&D focused on science of the immune system, genetics and advanced technologies

New leading Consumer Healthcare company with category leading power brands and science and consumer insights
Significant progress on our priorities in 2020

Strengthened and advanced the pipeline

Competitive in-market execution

Disciplined cost control

Good progress on integration & separation

Progressed pandemic solutions

- 9 major approvals: BLENREP; Zejula 1LM OC; Trelegy asthma; Rukobia; Nucala HES; Benlysta LN; Tivicay (paediatric); Vocabria/Cabenuva (EU and Canada); Duvroq (Jp)
- Positive data presented: RSV vaccines, Benlysta LN, GSK’836 in HBV, BLENREP 2L MM, linerixibat cholestatic pruritis in PBC
- 9 pivotal study starts: including Zejula 1L NSCLC, MenABCWY, BLENREP 3L & 2L MM, RSV maternal, Vir-7831 COVID-19, NYESO SS

- Strong commercial execution driving new product growth
- Consumer Healthcare JV integration
- Good progress on separation and transformation activities, and cost base optimisation

- Advanced pandemic solutions; industry pledge on COVID vaccine access and safety
- Launched the AMR action fund together with 20+ partners to address rise of antibiotic resistant infections
- New environmental targets: net zero impact on climate and net positive impact on nature by 2030

HES, Hypereosinophilic syndrome; MM: multiple myeloma; PBC: primary biliary cholangitis; NSCLC: non-small cell lung cancer; LN, lupus nephritis; SS: synovial sarcoma; AMR: anti-microbial resistance; Jp, Japan; OC: ovarian cancer; HBV: hepatitis B
### Science

- 60 vaccines and medicines in our pipeline with >20 late-stage assets and >10 with blockbuster potential

### Technology

- Significant progress in rebuilding Oncology, with a focus on immunology – both IO and cell therapy
  - Highlighting today: **BLENREP, feladilimab, GSK’608 CD96**

### Culture

- Best in class Infectious Disease portfolio in Vaccines and Pharma
  - Highlighting today: **RSV OA vaccine, Cabenuva, cabotegravir LA PrEP, VIR-7831**

- Clear focus on life cycle innovation and building blockbusters to maximise value
  - Highlighting today: **Nucala/GSK’294 IL-5 LA**

- Multiple important catalysts in 2021
## Strong R&D pipeline

### 18 vaccines and 42 medicines

<table>
<thead>
<tr>
<th>First time in human/POM (Phase 1)</th>
<th>Proof of concept (Phase 1b/2)</th>
<th>Pivotal (Phase 2/3 / Registration)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3858279* (CCL17 inhibitor) OA pain</td>
<td>3640254 (maturation inhibitor) HIV</td>
<td>Benlysta² + Rituxan SLE**</td>
</tr>
<tr>
<td>3511294* (LA anti-IL5 antagonist) asthma</td>
<td>3228363* (HBV ASO) HBV</td>
<td>cabotegravir LA + rilpivirine* LA HIV</td>
</tr>
<tr>
<td>3745417 (STING agonist) cancer</td>
<td>linericibat (IBATI) cholestatic pruritus in PBC</td>
<td>cabotegravir LA HIV PrEP</td>
</tr>
<tr>
<td>3349171* (hPGD2 synthase inhibitor) DMD</td>
<td>3326595* (PRMT5 inhibitor) cancer</td>
<td>daprodrugst (HIF-PHI) anemia</td>
</tr>
<tr>
<td>3186099* (CRK-12 inhibitor) visceral leishmaniasis</td>
<td>cobolimab* (TSR-022, TIM-3 antagonist) cancer</td>
<td>NucaLA COPD / nasal polyps</td>
</tr>
<tr>
<td>3810109* (broadly neutralizing antibody) HIV</td>
<td>3036656* (leucyl t-RNA inhibitor) TB</td>
<td>BLENREP* (BCMA ADC) multiple myeloma</td>
</tr>
<tr>
<td>3537142* (NYE01 ImmTAC) cancer</td>
<td>2831781* (aLAG3 depleting) ulcerative colitis</td>
<td>Zejula* (PARP inhibitor) ovarian cancer**</td>
</tr>
<tr>
<td>3368715* (Type 1 PRMT inhibitor) cancer</td>
<td>407436* (TSR-033, LAG3 antagonist) cancer</td>
<td>dostarlimab* (PD-1 antagonist) dMMR/MSI-H EC</td>
</tr>
<tr>
<td>2798745* (TRPV4 blocker) DME</td>
<td>Menvoe liquid</td>
<td>bintrufusp alfa* (TGFβ trap/anti-PDL1) BTC**</td>
</tr>
<tr>
<td>6097608* (CD96) cancer</td>
<td>RSV paediatric</td>
<td>otilimab* (3196165, aGM-CSF inhibitor) RA**</td>
</tr>
<tr>
<td>2982772 (RIP1-k) psoriasis</td>
<td>RSV older adults**</td>
<td>gepotidacin* (2140944) uUTI and GC</td>
</tr>
<tr>
<td>3882347* (FimH antagonist) uUTI</td>
<td>Therapeutic HBV**</td>
<td>3359609* (ICOS receptor agonist) HNSCC**</td>
</tr>
<tr>
<td>3739937 (maturation inhibitor) HIV</td>
<td>Malaria* (fractional dose)</td>
<td>letetresgene-autoleucel* (3377794, NY-ESO-1 TCR) SS**</td>
</tr>
<tr>
<td>3923868 (PI4kβ inhibitor) viral COPD exacerbations</td>
<td>Shigella*</td>
<td>4182136* (VIR-7831) COVID-19</td>
</tr>
<tr>
<td>3901961* (CD8 TCR) cancer</td>
<td></td>
<td><strong>Shingrix immuno-compromised</strong></td>
</tr>
<tr>
<td>3845097* (TGFbR2 TCR) cancer</td>
<td></td>
<td>Bexsero infants (US)</td>
</tr>
<tr>
<td>3494245* (proteasome inhibitor) visceral leishmaniasis</td>
<td></td>
<td>MMR (US)</td>
</tr>
<tr>
<td>3915393* (TG2 Inhibitor) celiac disease</td>
<td></td>
<td>Rotarix liquid (US)</td>
</tr>
<tr>
<td>2556286* (Mtb inhibitor) TB</td>
<td></td>
<td>MenABCWY</td>
</tr>
<tr>
<td>3729098* (ethionamide repressor inhibitor) TB</td>
<td></td>
<td>RSV maternal*</td>
</tr>
<tr>
<td>C. difficile*</td>
<td></td>
<td>COVID-19 (Medicago)**</td>
</tr>
<tr>
<td>SAM (rabies model)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S. aureus*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19 (Sanofi)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19 (Clover Biopharmaceuticals)**</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*In-license or other alliance relationship with third party **Additional indications also under investigation *GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations


Key:
- Oncology
- Immune/Other
- Infectious Diseases (Rx)
- Infectious Diseases (Vx)

Note: only the most advanced indications are shown for each asset
High value late-stage pipeline; >10 potential blockbuster launches by 2026

2021 - 2022
- Cabenuva: HIV
- Cabotegravir: LA PrEP, HIV
- VIR-7831: COVID
- otilimab: COVID*
- bintrafusp: solid tumours
- dostarlimab: MSI-H 2L EC+pan tumour
- Vaccine adjuvant: COVID

2023 - 2026
- RSV: older adults
- gepotidacin: uUTI
- HBV ASO: hepatitis B
- IL-5 LA: asthma
- feladilimab: HNSCC/NSCLC
- bintrafusp: NSCLC/solid tumours
- daprodustat: CKD anaemia
- dostarlimab: combos/solid tumours
- otilimab: RA
- RSV: maternal
- TIM-3: NSCLC
- MenABCWY: meningitis
- NYESO TCR-T: SS/NSCLC
- Linerixibat: PBS
- CD96: cancer
- GSK’254: HIV
- BLENREPS: earlier line MM
- Zejula: NSCLC
- Nucala: COPD

*Otilimab COVID currently in Ph2

New product
Lifecycle innovation
Sales potential >US$1BN
## Innovative oncology portfolio

15 oncology assets in development (12 in I-O & cell therapy)

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Phase 1 (FTIH)</th>
<th>Phase 2 (dose expansion)</th>
<th>Phase 2/3 (pivotal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zejula (niraparib)</td>
<td>First line maintenance ovarian, other solid tumours under investigation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLENREP (belantamab mafodotin)†</td>
<td>Multiple myeloma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TGF-beta trap/PD-L1 antagonist (bintrafusp alfa)§</td>
<td>NSCLC, BTC, cervical, other solid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD-1 antagonist (dostarlimab)</td>
<td>Solid tumours (including endometrial, ovarian, NSCLC, Cervical, other MSI-H tumours)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICOS receptor agonist (feladilimab, GSK3359609)†+</td>
<td>NSCLC, HNSCC, other solid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NY-ESO-1 TCR T cells (GSK3377794)†</td>
<td>Sarcoma, NSCLC, multiple myeloma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIM-3 antagonist (cobolimab, TSR-022)</td>
<td>Solid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRMT5 inhibitor (GSK3326595)†</td>
<td>Solid tumours, heme malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NY-ESO-1 ImmTAC® (GSK3537142) ‡</td>
<td>Solid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD96 (GSK6097608)</td>
<td>Solid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAG-3 antagonist (TSR-033)</td>
<td>Solid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STING agonist (GSK3745417)</td>
<td>Solid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD8 TCR T cells (GSK3901961)†</td>
<td>Solid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TGFbR2 TCR T cells (GSK3845097)†</td>
<td>Solid tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 1 PRMT inhibitor (GSK3368715)†</td>
<td>Solid tumours, DLBCL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 In-licensure or other partnership with third party; 1 COS HNSCC Phase 2/3 study with registrational potential
2 Option based alliance with Immunocore Ltd. ImmTAC is a registered trademark of Immunocore Ltd.
3 Being developed in a strategic global alliance between GSK and Merck KGaA, Darmstadt, Germany
4 Re-categorised from phase II to I following refinement of phase definitions

FTIH, first time in human; NSCLC, non small cell lung cancer; HNSCC, Head and neck squamous cell carcinoma; BTC, biliary tract cancer

---

**Legend:**
- **Orange:** Synthetic lethality
- **Blue:** Immuno-oncology
- **Green:** Oncology cell therapy
- **Pink:** Cancer epigenetics
BLENREP: first-in-class BCMA targeted therapeutic for multiple myeloma

First BCMA targeted agent approved

- DREAMM-2 demonstrated clinically meaningful benefit in heavily pre-treated relapsed/refractory multiple myeloma
- Commercial launch underway in US and Germany; strong initial demand

Investigating synergistic novel combinations

- DREAMM-5 platform study with ≥3 novel combinations; preliminary GSI combination data expected 2021
- DREAMM-4 combination with pembrolizumab; data in-house, presentation expected 1H21

Development in earlier lines

Studies ongoing to optimize dose for combinations with SoC and novel agents in earlier lines

Phase 1/2 ALGONQUIN study (Blenrep plus PomDex; ≥1 prior therapy RRMM) presented at ASH 2020:

<table>
<thead>
<tr>
<th>Dose</th>
<th>ORR (%)</th>
<th>VGPR (%)</th>
<th>PR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.92 mg/kg n=11</td>
<td>18%</td>
<td>64%</td>
<td>21%</td>
</tr>
<tr>
<td>2.5 mg/kg Combined n=19</td>
<td>26%</td>
<td>47%</td>
<td>21%</td>
</tr>
<tr>
<td>1.92 mg/kg n=12</td>
<td>17%</td>
<td>15%</td>
<td>35%</td>
</tr>
<tr>
<td>2.5 mg/kg Combined n=20</td>
<td>15%</td>
<td>70%</td>
<td>15%</td>
</tr>
</tbody>
</table>

Pivotal 2L+ DREAMM 7 & 8 combination studies initiated 2020; results anticipated 2022-2023

By IMWG uniform response criteria 2016; ORR, overall response rate; PR, partial response; VGPR, very good partial response. Combined-2.5mg/kg include single, loading and split doses; Keratopathy by exam finding, *visual acuity change 20/50 or worse in better seeing eye. Trudel, et al ASH 2020

GSI, gamma secretase inhibitor; SoC, standard of care
Feladilimab, ICOS receptor agonist: several near-term catalysts anticipated

**Novel I-O target, expected to modulate T-cell dynamics**

- Activity observed in monotherapy and PD-1 combo
- Durable responses seen with pembro combo; median PFS of 4.2 months, median OS of 13.1 months³
- ORR of 24% (12% CR, 12% PR lasting ≥6 months)³

**Clinical development approach for feladilimab (GSK’609)**

- Initial development in 1L relapsed/metastatic HNSCC¹
  - >500k people diagnosed globally/year
  - **INDUCE-3**: ongoing Ph2/3 (combo with pembrolizumab); interim analysis 1H 2021 to ungate Phase 3
  - **INDUCE-4**: ongoing Phase 2/3 (combo with pembrolizumab and chemo); data readout 2024

- Data in other solid tumors expected in 2021
  - **INDUCE-1**: FTIH open label study; data in other solid tumors expected in 1H 2021
  - **ENTRÉE lung**: in NSCLC² (combo with docetaxel) expected 1H 2021

---

Innovative approach to the CD226 axis (anti-CD96, anti-PVRIG)

CD226 axis plays an important role in cancer immune surveillance

- CD226 is a costimulatory receptor on T and NK cells that interacts with CD155 and CD112 on tumor cells
- TIGIT, CD96 and PVRIG are immune checkpoints expressed on various T and NK cell subsets
- TIGIT and CD96 bind to CD155, and PVRIG binds to CD112, to sequester them and prevent their activation of CD226
- mAbs to TIGIT, CD96 and PVRIG permit CD226 interactions with CD155 and CD112, and result in antitumor activity

- GSK’608 (anti-CD96): potential first-in-class mAb, Ph1 underway
- SRF813 (anti-PVRIG): potential best-in-class mAb, Ph1 start 2022
- Dostarlimab (anti-PD-1): potential for combinations
  Potential partner of choice for TIGIT combinations
World leader in Infectious Diseases

32 vaccines and medicines in development

<table>
<thead>
<tr>
<th>First time in human/POM (Phase 1)</th>
<th>Proof of concept (Phase 1b/2)</th>
<th>Pivotal (Phase 2/3 /Registration)</th>
<th>Marketed</th>
</tr>
</thead>
<tbody>
<tr>
<td>3168699* (CRK-12 inhibitor) visceral leishmaniasis</td>
<td>3640254 (maturation inhibitor) HIV</td>
<td>cabotegravir LA + rilpivirine* LA HIV</td>
<td>Rukobia</td>
</tr>
<tr>
<td>3810109* (broadly neutralizing antibody) HIV</td>
<td>3228836* (HBV ASO) HBV</td>
<td>cabotegravir LA HIV PrEP</td>
<td>Dovato</td>
</tr>
<tr>
<td>3882347* (FimH antagonist) uUTI</td>
<td>3036656* (leucyl-tRNA inhibitor) TB</td>
<td>gepotidacin* (2140944) uUTI and GC</td>
<td>Juluca</td>
</tr>
<tr>
<td>3739937 (maturation inhibitor) HIV</td>
<td>Menveo liquid</td>
<td>4182136* (VIR-7831) COVID-19</td>
<td>Tivicay</td>
</tr>
<tr>
<td>3494245* (proteasome inh) visceral leishmaniasis</td>
<td>RSV paediatric</td>
<td>Shingrix immuno-compromised*</td>
<td>Triumeq</td>
</tr>
<tr>
<td>2556286* (Mtb inhibitor) TB</td>
<td>RSV older adults*</td>
<td>Bexsero infants (US)</td>
<td>Epzicom / Kivexa</td>
</tr>
<tr>
<td>3729098* (ethonamide repressor inhibitor) TB</td>
<td>Therapeutic HBV*</td>
<td>MMR (US)</td>
<td>Selzentry</td>
</tr>
<tr>
<td>C. difficile*</td>
<td>Malaria* (fractional dose)</td>
<td>Rotarix liquid (US)</td>
<td>Zinnat</td>
</tr>
<tr>
<td>SAM (rabies model)</td>
<td>Shigella*</td>
<td>MenABCWY</td>
<td>Zeffix</td>
</tr>
<tr>
<td>S. aureus*</td>
<td></td>
<td>RSV maternal*</td>
<td>Viread</td>
</tr>
<tr>
<td>COVID-19 (Sanofi)*</td>
<td></td>
<td>COVID-19 (Medicago)*</td>
<td>Augmentin</td>
</tr>
<tr>
<td>COVID-19 (Clover Biopharmaceuticals)*</td>
<td></td>
<td></td>
<td>Shingrix</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bexsero</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Menveo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fluarix</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Priorix / Priorix Tetra / Varilix</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Infanrix / Pediarix / Boostrix</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Synflorix</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hepatitis vaccines</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rotarix</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cervarix</td>
</tr>
</tbody>
</table>

*In-license or other alliance relationship with third party | GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations | POM: proof of mechanism, TB: tuberculosis; uUTI: uncomplicated urinary tract infection; GC: gonorrhoea

12 vaccines and medicines in development:
RSV older adults: major opportunity with high unmet need

Significant opportunity; first-in-class potential

- Features pre-fusion antigen combined with AS01 adjuvant
- Proven adjuvant to stimulate greater immune response in older adult population
- Substantial US disease burden\(^1\) with 177k hospitalisations and 14k deaths per year in 65+ age group
- 70m adults age 60+ in US\(^2\); >300m developed regions\(^3\)
- \(\sim\)2/3 of older US adults receive flu or pneumococcal vaccines\(^4\)

Phase 2: compelling antibody response and T cell restoration

- Ph3 to start Q1 2021; initial data expected H2 2022*  

\*Timing dependent on RSV infection circulation during pandemic lockdowns

---

\(^1\) CDC: [https://www.cdc.gov/rsv/high-risk/older-adults.html](https://www.cdc.gov/rsv/high-risk/older-adults.html)  
\(^3\) United Nations World Population Prospects 2019  
\(^4\) CDC: [https://www.cdc.gov/nchs/products/databriefs/db281.htm](https://www.cdc.gov/nchs/products/databriefs/db281.htm)
Cabenuva*: unique long-acting regimen

- **Differentiated approach**: first and only once-monthly* complete LA HIV regimen; non inferior efficacy and comparable safety to daily oral regimens
- **Critical Need**: More than half of all PLHIV state that oral daily pills are a reminder of their HIV status and have hidden or disguised their medicine due to stigma
- **Strong patient preference**: >97% of patients in pivotal ATLAS and FLAIR studies preferred LA regimen vs daily oral therapy
- **Commercially ready**: sales force ready to launch and support HCPs in successful Cabenuva adoption

US approval expected 1Q 2021

Cabotegravir long-acting: superior to oral daily PrEP

- **Superior efficacy**: Cabotegravir LA IM every 2 months:
  - 66% more effective than oral daily FTC/TDF in MSM*
  - 89% more effective than oral daily FTC/TDF in women
- **Patient preference**: Reduces stigma and adherence issues of daily dosing
- **$2bn market**: >200k US PrEP patients today, but up to 1.2m could benefit

US submission expected mid 2021

*Approved as Vocabria + Rekambys in EU; approved every two-monthly dosing in EU
LA, long-acting; PLHIV, people living with HIV; CI, confidence interval; MSM, men who have sex with men

PrEP source: Landovitz RJ et al. AIDS 2020, #OAXLB01
VIR-7831: potential best-in-class COVID-19 antibody

Broad clinical development programme:
COMET-ICE Ph3 study ongoing in patients at high risk of hospitalisation; data expected 1Q21
ACTIV-3 Ph3 study initiated December 2020 in hospitalised patients with COVID-19
Further studies planned to explore full potential

*SARS-CoV-2, severe acute respiratory syndrome coronavirus and other CoVs
Extending IL-5 leadership through Nucala LCI and next generation long-acting antibody

Leadership in IL-5

- **Category-leading monthly IL5**: sales annualising at >£1bn*
- **Significant opportunity**: only 27% of US patients with SEA¹ receive a biologic
- **Maintaining leadership through LCI**:  
  - Paediatric patients  
  - Auto-injector for at home use  
  - 1st biologic approved for EGPA² and HES³  
  - Positive Phase 3 data in NP⁴  
  - Phase 3 study in COPD ongoing

GSK3511294: next generation IL-5 biologic

- **Extending leadership**: potential to be first extended-release biologic for SEA
- **Attractive clinical profile**: engineered for high affinity and long-lasting suppression of IL-5, underscored by positive Phase 1 data
- **Patient convenience**: single sc injection once every 6 months
- **High probability of success**: based on validated MoA and data in-hand

Pivotal Phase 3 to start 1Q 2021; results expected 2024

---

* Based on 3Q 2020 sales of £251m, 1. Severe Eosinophilic Asthma  2. Eosinophilic granulomatosis with polyangiitis 3. Hypereosinophilic syndrome  4. Nasal Polyps; LCI, life cycle innovation; MoA, mechanism of action
BD has been key to augmenting our pipeline and providing access to differentiating technologies

### Strengthening the pipeline in key areas of focus – immunology and genetics

- **Zejula (PARP inhibitor)**
- **dostarlimab (PD-1 antagonist)**
- **TSR-022 (TIM-3), TSR-033 (LAG-3)**
- **bintrafusp alfa (TGFβ trap/anti-PDL1)**
- **SRF813 (anti-PVRIG)**
- **3 pre-clinical synthetic lethal programs MAT2A, Pol Theta and Werner Helicase**
- **anti-CD96 (GSK’608)**
- **~30 ongoing pre-clinical programmes**
- **VIR 7831/7832 (GSK’136, SARS-CoV2)**

### Best-in-class functional genomics to help identify better targets

- **Formed Laboratory for Genomics Research**
  - 3 projects initiated on genetics of disease in oncology (2) and neurodegeneration (1)
- **5-yr research collaboration in genetics and genomics**
- **Synthetic viability target discovery collaboration**

### Enhancing our cell therapy capabilities

- **Optimising our T cell programmes (NY-ESO)**
- **Identifying next-generation T cell receptor therapeutics with a focus on solid tumours**
# Multiple important catalysts in 2021

## Anticipated submissions and approvals

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabenuva (US)</td>
<td>HIV</td>
</tr>
<tr>
<td>Cabotegravir LA PrEP</td>
<td>HIV</td>
</tr>
<tr>
<td>Nucala</td>
<td>NP (HES and EGPA in EU)</td>
</tr>
<tr>
<td>Dostarlimab</td>
<td>2L EC</td>
</tr>
<tr>
<td>COVID-19: otilimab, VIR-7831, vaccines</td>
<td></td>
</tr>
</tbody>
</table>

## Pivotal data

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIR-7831</td>
<td>COVID-19 (COMET-ICE)</td>
</tr>
<tr>
<td>Daprodustat</td>
<td>renal anaemia</td>
</tr>
<tr>
<td>Dostarlimab combo 2L EC (RUBY)</td>
<td></td>
</tr>
<tr>
<td>Binfrafusp alfa</td>
<td>BTC</td>
</tr>
<tr>
<td>COVID-19 vaccines</td>
<td></td>
</tr>
</tbody>
</table>

## Proof of concept*

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Otilimab</td>
<td>COVID-19 (OSCAR)</td>
</tr>
<tr>
<td>Feladilimab</td>
<td>NSCLC (ENTRÉE)</td>
</tr>
<tr>
<td>NY-ESO</td>
<td>NSCLC</td>
</tr>
<tr>
<td>Cobolimab</td>
<td>NSCLC</td>
</tr>
<tr>
<td>LAG-3</td>
<td>in ulcerative colitis*</td>
</tr>
<tr>
<td>BLENREP plus GSI</td>
<td>in MM**</td>
</tr>
<tr>
<td>S. Aureus vaccine*</td>
<td></td>
</tr>
</tbody>
</table>

---

*Not comprehensive, *interim data, **preliminary data

NP: Nasal polyposis; HES: hypereosinophilic syndrome; EGPA, eosinophilic granulomatosis with polyangiitis; EC, endometrial cancer; dMMR, deficient MisMatch Repair; OC ovarian cancer; BTC, biliary tract cancer; RSV: respiratory syncytial virus; PBC, primary biliary cholangitis; NSCLC: non-small cell lung cancer; GSI, gamma secretase inhibitors; MM, multiple myeloma
Building a sustainable pipeline of transformational vaccines and medicines

**Science**

- 60 vaccines and medicines in our pipeline with >20 late-stage assets and >10 with blockbuster potential
- Significant progress in rebuilding Oncology, with a focus on immunology – both IO and cell therapy
  - Highlighting today: BLENREP, feladilimab, GSK’608 CD96

**Technology**

- Best in class Infectious Disease portfolio in Vaccines and Pharma
  - Highlighting today: RSV OA vaccine, Cabenuva, cabotegravir LA PrEP, VIR-7831

**Culture**

- Clear focus on life cycle innovation and building blockbusters to maximise value
  - Highlighting today: Nucala/GSK’294 IL-5 LA
- Multiple important catalysts in 2021
Q&A